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1 In,eduction 
Over thuty years ago it was proposed that the 
mttom of cells may be controlled by a negative feed- 
back mechanism [ 1,2], an idea winch was substantially 
apphed to the regulation of epidermal cell growth 
[3,4] These workers uggested that endogenous 
mitotic minbltors were produced by cells winch would 
mlublt only that speofic cell type Historically, these 
minbRors have been referred to as 'chalones', from 
the Greek word meanmg to brake or slow down. The 
Instory of the chalone concept has been rewewed [5] 
and is too vast to be treated here. The primary charac- 
tensUcs o fa  classac halone have been defmed as: (1) 
total cell specificity, (2) species non-specific, (3) revers- 
lble; and (4) non-cytotoxlc. Houck [6] covered the hter- 
ature up to 1976 m detml and summarized the major 
biological ewdence for the existence of chalones, a
point whach has not been unequivocally estabhshed 
It is a general cntlclsm of chalone research that the 
theories have always been far m advance of the data. 
This has come about possibly because of the inherent 
difficulties m measunng cell minbltlon m a specific 
manner, as opposed to measurement of cell growth 
stmmlatlon However, it may not be justified to dis- 
card an attractive theory sunply due to techmcal dlf- 
ficullaes and weak supporting data 
Here we are not concerned with the phenomenol- 
ogy of ehalones and consider only recent develop- 
ments m several areas wluch show progress toward 
purification and understanchng the chemistry of van- 
ous ehalones Obvmusly, much of the biology and 
theory will not be relevant until the purified mlubttor 
is at hand Thus we do not present a comprehenrave 
review of the hterature and cite orfiy general or repre- 
sentatave papers m any area We consider two specific 
chalones in detail, lymphocyte and granulocyte, and 
several others briefly Considerable progress has been 
made with these two and they may be representative 
ofchalones m general We also mention some prob- 
lems reeogmzed m research on growth mlubttors 
2 Chalone systems 
2 1 Lymphocyte chalone 
lninbltors of lymphocyte transformahon have been 
shown in vitro m extracts of lymphoid tissue [7-15] 
Tlus work (rewewed [ 16-18 ]) showed that extracts 
of spleen, thymus, or lymph nodes, contained a factor 
(or factors) with an app.M r of 10 000-50 000 as 
determined by ultrafdtratton, wluch would specific- 
ally mlublt the lectm-stamnlated transformation f
lymphocytes as well as graft-versus-host response and 
allograft rejectaon [ 19-21 ] Subsequently it was found 
[ 18,22-24] that part or all of the actlwty could be 
present at a much lower M r Pre-treatment 9f the 
extracts with nbonuclease, acid, or streptomycin sul- 
fate could cause the minbttory actMty to pass through 
a 10 000M t ultrafflter and be retmned on a column 
of Sephadex G-25 The recognition of the low M r 
nature of lymphocyte chalone has accelerated progress 
m xts purification and (as always has been the case m 
chalone research) presented several new problems We 
present first the recent steps toward the punficatton 
of tins factor 
Most progress m the purification of an lmmunosup- 
presstve factor has been reported by Lenfant et al 
[25,26] working with an extract of spleen Ttus tsola- 
tlOrt scheme also gives some Insight rote the possible 
chemical nature of lymphocyte chalone The actawty 
is extracted from spleen and a lowM r fraction 
obtained by ultrat'fltration Tins is absorbed to and 
eluted from neutral alumina by organic solvent mix- 
tures, fracttonated on a Sephadex LH-20 column m 
an ethanol water mixture, and subjected to dtmqayer 
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chromatography on cellulose plates. At this stage of 
purity, the factor was active at a dose of 2 X 1 O-’ mg 
a fraction of Mr 10 000-50 000 which exhibited the 
properties of a lymphocyte chalone. Similar material 
in reducing the haemolysin plaque-forming response could be prepared from media conditioned by cultured 
of mouse lymphocytes. They subjected their most lymphoid cell lines [ 171. Treatment of the ultrafil- 
purified fraction to high-pressure liquid chromatog trate from thymus with ribonuclease would enable 
raphy (HPLC) where the activity was one of the last the activity to pass through a 10 000 Mr filter and be 
components eluted from the C ,s-reversed phase retained above a 500 Mr filter [22]. This suggested to 
column. No data has been forthcoming concerning us that the chalone may become associated with 
the structure of their factor, nor on its specificity. It RNasesensitive molecules during tissue extraction, 
should be noted here that the authors reported that possibly transfer RNA of this molecular size. Gel fil- 
the activity was lost upon prolonged storage at -20°C tration on columns of Sephadex G-25 confirmed the 
or by repeated freeze-thawing, which may hamper low M, nature of the activity [ 18,281 and indicated 
efforts to accumulate quantities of the active factor! that it was in fact <2000 Mr. 
Several other research groups, including ourselves, 
have reported on the purification of low Mr inhibitors 
of lymphocytes. Maschler and Maurer [27] have begun 
the isolation of an Mr 1000-2000 chalone from 
bovine thymus which will inhibit colony growth of 
lymphocytes under serum free conditions. Two activ- 
ities were observed by ultrafiltration, an unstable 
activity at M, 10 000-30 000 and a stable activity at 
Mr < 10 000. The low M, fraction eluted after bacitra- 
tin on Bio-Gel P6 columns, indicating an Mr < 1400, 
and could be partially purified by DEAE-cellulose 
columns. This fraction was carefully tested and found 
to be noncytotoxic and reversible, both properties 
necessary for a chalone. The activity, in contrast to 
that reported by Lenfant , was stable to repeated 
freeze-thaw cycles, and to storage at 4°C up to 
120 days or 37°C for 24 h. The authors suggested, as 
have others, that the higher Mr inhibitory activity, 
which was unstable and variable in yield, was due to 
large carrier molecules which associated with the 
smaller factor. 
The low M, fraction is isolated from thymus by 
60% ethanol extraction followed by acetone precipita- 
tion. The crude fraction is then separated on a column 
of Sephadex G-25 which demonstrates only one active 
area when aliquots are added to MLC in the presence 
of human serum (fig.lA). The activity is detected 
w 
GrundboeckJusko [24] has reported very similar 
results to the above in antimitotic fractions isolated 
from bovine spleen and assayed in vivo by examining 
the number of mitotic cells in lymphoid organs of 
treated animals. Two activities were observed at 
Mr 38 000 and 2 100 from smooth microsomes and 
one at M, 2500 extracted from rough microsomal 
fractions. From biological studies, it was concluded 
that the M, 38 000 inhibitor was specific for B-cells 
while the smaller species demonstrated specificity for 
the Tcells. 
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We have found both high and low Mr inhibitory 
activity in our studies of a thymus derived factor 
which inhibits the alloantigen stimulation of lympho- 
cytes in mixed leukocyte culture (MLC). In the origi- 
nal studies [ 17,181, ultrafiltration was used to prepare 
Fig.1. Column profile of 60% ethanol soluble fraction from 
calf thymus resolved on Sephadex G-25 (A) and then 
Sephadex G-10 (B). Column fractions are screened for A,,, 
(-) and inhibition of the mixed lymphocyte culture in 
human serum determined by [ ‘Hlthymidine incorporation 
(o---o) and by visualestimation (m). (A) The pool indicated 
I was lyophillzed and applied to the Sephadex G-10 column. 
(B) Pool I indicates area of activity determined by both 
methods, pool II, the area of elution of NaCI, and pool III, 
fraction containing inhibitors of label incorporation only. 
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both by visual examination of the cultures for lym- 
phoblast formation and by labeled thymidine incor- 
poration. The active area is concentrated and applied 
to a column of Sephadex G-10, the elution pattern 
of which is shown in tig.lB. This column separates 
the low M, inhibitor (pool I) from the salt (pool II) 
and unlabeled nucleotides (pool III). The pool III 
materiaI only inhibits labeled thymidine incorpora- 
tion into st~ulated lymphocytes without any effect 
upon morphological transformation. This will be dis- 
cussed in more detail in section 3 .l . Although consid- 
erably cleaner than the crude starting material, the 
inhibitory fraction from the Sephadex G-10 column is 
still extremely complex, containing at least 40 distinct 
components by analytical HPLC analysis (D. Barrantes, 
unpublished). 
It is difficult to ascertain true Mr values using 
exclusion chromatography since chemical adsorption 
effects must be considered. The solubility properties 
of this active fraction indicate that it has considerable 
hydrophobic nature. 
It can be generally noted now that lymphocyte 
inhibitory activity extracted from lymphoid tissue 
residues in a low Mr molecule which is either specific- 
ally carried by a much larger molecule, or becomes 
associated with one during extraction procedures. It
is this association which sometimes allows the inhibit- 
ory activity to masquerade as a much larger molecule. 
The low M, of this inhibitor, while making the isola- 
tion somewhat more difficult, raises the possibilities 
of eventual synthesis of active molecules which could 
be of extreme importance in ~munosuppression. 
The relationship of lymphocyte chalones to other 
inhibitors of lymphocytes uch as inhibitory lympho- 
kines, lymphotoxin, inhibitor of DNA synthesis (IDS), 
and soluble immune suppressor substance (SIRS) 
[ 16,291 or inhibitory activity from thymus-derived 
~yrno~ peptide fractions 130-321 or FTS (factor 
thymique serique) [3 1,331 is too complex a topic to 
be fairly treated in this limited space. On the surface 
it seems that nomenclature may be the major source 
of differences as the word ‘chalone’ is not treated with 
universal respect among most investigators. 
2.2. Grmulocyte chidone 
Another example of a low Mr. inhibitor is that of 
the granulocyte chalone. Early work on the granulo- 
cyte chalone, its biology and role in control of gran- 
ulopoiesis has been reviewed [34,35] and the methods 
for its assay have been examined [36]. Briefly, it has 
been demonstrated by numerous groups that extracts 
of granulocytes, or media conditioned by contact 
with granulocytes, reversibly inhibited ~~ulocyte 
precursor cells in cultures of bone marrow. This activ- 
ity has been shown to exhibit the classic halone prop 
erties of reversibility, species non-specificity, cell-spe- 
cificity, and non-cytotoxicity. 
In a series of papers from the laboratory of W. R. 
Paukovits, the long, often ~omp~cated, steps in the 
purification of this chalone activity are detailed. 
Paukovits 1371 and others [38] found that the inhib- 
itory activity present in granulocyte conditioned 
media could pass through a 10 000 Mr ultrafilter and 
be retained above a 500&f, filter. This was in agree- 
ment with the elution from Sephadex G-75 which 
indicated an Mr of 4000 [39]. The activity was found 
to migrate on several other types of Sephadex and 
Bio-Gel P gels in a manner to suggest considerably 
lower M,, the activity usually eluting between the 
leucine and thymidine markers. Finally 140,411 it
was demonstrated that Sephadex G-l 0 could provide 
the needed resolution and the chalone would elute 
from this gel matrix ahead of the salt and thymidine 
peaks. This indicated an Mr of -600. The activity did 
not stick to Dowex resins but could be further puri- 
fied by thin-layer chromato~aphy on cellulose. 
Maschler and Maurer [42] have found similar 
active fractions in either culture media or ascites fluid. 
Sephadex G-25 columns indicating an Mr <lO 000 
and in some cases -500. Another group [43] have not 
presented their preparation i  detail but indicate activ- 
ity at an &fr of 500-1000 for a chatone xtracted 
from leukocyte conditioned media. 
The observation that the granulocyte chalone activ- 
ity was dependent upon thiol groups [44], has resulted 
in considerable progress in the purification. The activ- 
ity from leukocyte conditioned medium, referred to 
as gr~ulopoie~s ~biting factor (GIF), was absorbed 
to and eluted from thiol propyl Sepharose followed 
by a reversed phase Cra-column and ion-exchange 
chromatography [45]. After these techniques a single 
spot was demonstrated in several thin-layer chroma- 
tography (TLC) systems. Other analyses have indi- 
cated that the activity resides in an M; 500-600 acidic 
peptide with an N-terminal pyroglutamyl residue, a
thiol group, three carbonyl groups and one lysine 
amino group. Presumably, further analysis must await 
the purification of greater amounts of material, but, 
with the data indicated already, model peptides can 
be synthesized and tested. 
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An interesting note here is that mouse lymphoma described as being of high M, also by ultrafiltration 
cell lines that demonstrate thiol dependence for cul- and has been shown to be similar to lymphocyte chal- 
ture may also secrete a thiol containing, small M,, one in its sensitivity to RNAse and elution from 
mitotic inhibitor [46]. Sephadex G-25 [ 18,221. 
2.3. Other chalone systems 
We now briefly discuss several other chalones, or 
chalone-like activities, which have been suggested as 
being of low Mr and of hydrophobic nature. 
Some interesting results have been presented con- 
cerning the properties of an inhibitor of the JB-1 
ascites cells. These cells have been shown [47] to pro- 
duce an inhibitor of Mr 10 000-50 000 with proper- 
ties of a Grchalone. A preliminary report has appeared 
[48], which has suggested a considerably lower Mr. 
The inhibitor has been isolated from labeled ascites 
fluid by columns of DEAEcellulose, Sephadex G-l 5, 
and AGlX-2 resin. This procedure yields a low M, 
(400-700), acidic, and hydrophobic peptide. JB-1 
ascites cells are >lO-20-times more sensitive to the 
inhibitor than other cells. The properties of the JB-7 
inhibitor are strikingly similar to those reported for 
the granulocyte chalone of Paukovits. 
The epidermal control mechanisms, history, and 
biology have been reviewed [54-561 and are too 
extensive to be mentioned here. It is commonly 
accepted that there exist two epidermal chalones, the 
G, and Gz. The G2 chalone halts cell division at a 
point in the cell cycle after S phase prior to mitosis 
and is of high app. Mr ,20 00045 000. Considerable 
heterogeniety has been noted in the material with 
activity noted as low as Mr 3000 [56-581. 
It has been suggested that the control of liver 
growth and regeneration is under the control of a 
chalone mechanism [49]. The traditional extraction 
procedure involves extraction of liver tissue and frac- 
tionation by cold ethanol solutions, the chalone activ- 
ity was usually found in a 60-87% ethanol precipi- 
tated fraction. This material could be further frac- 
tionated by ultrafiltration or chromatography on 
Sephadex G-25 [50,5 11. The Mr of this inhibitor has 
remained constant at -2000, not changing as much as 
some of the others. Additional steps have been added 
to the isolation scheme for this chalone [ 521 which 
has involved chromatography on Sephadex LH-20 fol- 
lowed by silica-gel and thin-layer chromatography on 
polysilicic acid-impregnated sheets. All these methods 
suggest a considerable hydrophobic nature for the 
chalone. Ammo acids were present in the active area 
on TLC but further purification is necessary for any 
firm conclusions. 
The epidermal Gr chalone owes much of its purifi- 
cation to the work reported by Marks [56]. Its proper- 
ties indicate that it is a quite stable molecule resistant 
to heating (IOO’C, 1 h), phenol, urea, 1 M formic acid 
at 70°C, ionic detergents at lOO”C, trypsin, pronase, 
and nucleases. The activity migrates at an app. M, 
>300 000 but could be reduced to -20 000 after 
rather brutal treatment with sodium dodecyl sulfate 
(SDS), dithiothreitol, blocking of -SH groups by 
iodoacetamide, and chromatography in 7 M urea and 
0.5% SDS. The activity could be further purified by 
ion exchange and phenol extraction and could depress 
epidermal mitosis at a dose of 0.05 -0.1 fig/mouse. Since 
the reported M, ranges from >300 000 to <I 0 000, 
Marks [59] mentions that the lowest is probably the 
truevalue. This does not seem unreasonable considering 
the stability of the active species and the extreme 
efforts necessary to reduce the activity to lower Mr. 
A small M, inhibitor of DNA synthesis which is 
specific for normal and malignant mammary cells has 
been described [53]. The inhibitor is purified from 
extracts of mammary tissue of Sephadex G-50, CM- 
Sephadex, and Sephadex G-25 columns, and had been 
suggested as being an M, 2000-3000 peptide. 
A summary of the progress toward the isolation of 
a chalone would be that many chalones, whether called 
that or not, are now recognized as being very stable, 
low M, compounds, probably peptides. A number of 
these active species previously demonstrated much 
higher M, values either due to specific or non-specific 
binding to carriers or due to very strong aggregation 
properties. Modern purification techniques such as 
HPLC show obvious promise in the resolution of com- 
plex tissue extracts containing chalone activities and 
should provide much information in the future. Obvi- 
ously the controversy surrounding the chalone con- 
cept will not resolve itself until puritied material is 
available in sufficient quantities. 
3. Critique 
A fibroblast chalone which would inhibit the 
growth of human diploid fibroblasts was originally 
3 .l . Assay artifacts 
No review of chalones could be considered com- 
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plete without first addressing itself to several problem 
areas which become apparent, and are constant criti- 
cisms, in the study of growth inhibiting substances. 
The most important are several artifacts which can 
commonly arise with the use of the popular in vitro 
proliferation assays. We will concern ourselves here 
with several high M, components which can alter cell 
growth and with certain small M, compounds which 
have received much attention in the literature, namely, 
the polyamines spermine and spermidine. Our men- 
tion of these effects, in reference to in vitro assays, 
must not be taken to imply that this type of assay is 
worthless, rather that careful attention must be paid 
to all possible influences on cell growth possible with 
tissue extracts. Whenever possible, reference to in vivo 
assay systems should be used to substantiate in vitro 
studies. 
The organ extract, or conditioned media, which 
are used as chalone sources contain a wide variety of 
components which can specifically or non-specifically 
influence cell division in vitro. As the most common 
method to ascertain if a particular cell population has 
undergone division is a pulse of labeled thymidine, we 
will consider briefly various pitfalls to be avoided. A 
number of these which have direct effect on labeled 
thymidine have been mentioned [36] and can include 
breakdown or alteration of thymidine by kinases 
released in tissue homogenates or by phosphorylases 
resulting from low level mycoplasma infections [60]. 
The latter must be considered especially when using 
conditioned media sources. 
Another macromolecular inhibitor which can arise 
in crude extracts as well as purified samples is bacte- 
rial infection and subsequent oxin production. A 
classic example of this problem is that of melanocyte 
chalone prepared from crude pig skin concentrate [61] 
which was subsequently shown to be associated with 
clostridium spores [62,63]. We have had similar expe- 
rience with commercially prepared spleen powder 
extracts [64]. 
Various nucleotides, including thymidine, are always 
present in small M, fractions from tissue [25,28] and 
can of course, inhibit labeled thymidine incorporation 
into cells by pool dilution and transport inhibition 
[36]. Interestingly, unlabeled nucleotides can be 
present in cell supernatants and conditioned media in 
sufficient amounts to cause inhibition of cellular 
uptake [65-681 and may result from breakdown of 
DNA from cell death present in the cultures [67,68]. 
All of the above influences on labeled thymidine can 
usually be controlled, and eliminated, if the data 
obtained by label incorporation is compared with 
results obtained by some non-isotopic method. We 
have found that some low M, fractions from thymus 
were about twice as active in an in vitro assay deter- 
mined by isotope as compared to visual determina- 
tions. This difference could be eliminated by passage 
of the active fraction through a Sephadex G-l 0 col- 
umn which (see tig.lB) separated a peak of activity 
with equal potency measured by isotope or visually 
from a peak of activity noted only by isotope incor- 
poration. The last peak has been identified as a mix- 
ture of thymidine and other nucleotides. 
3.2. Boblems with polyamines 
Perhaps the most interesting (at least the most con- 
troversial) small Mr inhibitors of cell proliferation to 
arise from chalone research recently has been the 
polyamines spermine and spermidine. Allen et al. [69] 
were among the first to suggest hat a chalone (lym- 
phocyte) was a complex of spermine and a higher Mr 
carrier molecule. They isolated a lymphocyte chalone 
by published procedures and found that the activity 
was dependent on the presence of bovine sera in the in 
vitro assays. Simultaneously, Byrd et al. [70] reported 
the potent inhibition of lymphocyte transformation 
by addition of synthetic spermine or spermidine to 
cultures containing bovine sera. Allen’s group further 
showed that polyamines could easily survive various 
extraction techniques and purification steps such as 
dialysis by associating with high M, carriers. 
The inhibition of authentic polyamines was inves- 
tigated by several groups [7 l-741 after the appear- 
ance of the above papers. Generally it was found that 
the inhibition of growth of lymphocytes and granulo- 
cytes by these polyamines was dependent on the pres- 
ence of bovine or human pregnancy sera. Polyamines 
were not inhibitors in the presence of human AB 
serum. In all cases the inhibitory activity has been 
associated with the presence of the enzymes diamine 
oxidase (DAO) or polyamme oxidase (PAO) in the 
serum. The absence of the DA0 and PA0 in human 
serum is perhaps not absolute and high levels can cause 
inhibition in the presence of polyamines [72]. Addi- 
tion of PA0 to normal human serum containing poly- 
amines causes inhibition of PHA-stimulated lympho- 
cytes and lymphoblastic cell lines [73]. 
The amine oxidases catalyze the oxidation of the 
amino propyl’moiety of polyamines to the correspond- 
ing amine aldehyde [ 751. These amino aldehydes and 
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the breakdown of product acrolein (HsC=CH-CHO) 
[76,77] are toxic to a variety of cultured cells. It is 
unknown if similar compounds are responsible for the 
inhibition observed in lymphocyte cultures, but it is not 
unlikely. However, the inhibition has been observed to 
be fully reversible (after even several days exposure to 
polyamines in the presence of bovine sera) and there- 
fore does not appear to be associated with gross cellu- 
lar toxicity. The degree of sensitivity to polyamine 
inhibition can vary considerably and this has been 
used [78] to eliminate fibroblasts from mixtures of 
fibroblasts and epithelial cells. Obviously more work 
must be done on identifying the active component 
resulting from the interaction of bovine sera and poly- 
amines and capable of inhibiting lymphocyte prolifer- 
ation. 
Other products of the oxidation of polyamines to 
aldehydes by DA0 and PA0 are possible in addition 
to acrolein. Under certain conditions [79,80] amino 
aldehydes can form various condensation products 
with themselves to form larger polycations. Some of 
these as yet uncharacterized products are potent inhib- 
itors of sodium transport [80]. 
The connections of polyamines, PAO, DAO, and 
certain immunosuppressed states is still of much inter- 
est. The two enzymes are increased in pregnancy [71], 
age [81], and polyamine levels increase in fetal and 
neoplastic growth [82]. It may be that such an associ- 
ation is mere coincidence and further research will 
resolve the difficulties. 
A number of investigators, in response to the 
papers of Allen and Byrd et al., have subsequently 
published statements that their particular chalone 
preparation does not contain polyamines or that the 
activity is present in human as well as bovine sera. 
This has been done for lymphocyte chalone isolated 
from spleen [83,84], and thymus [28,72,85] and leu- 
kocytes [43] and for the granulocyte chalone [43]. It 
is noteworthy that the effects of polyamine are impor- 
tant to eliminate wherever possible as these molecules 
seem able to appear at various M, fractions and can 
survive normal purification steps for large or small 
molecules. This is of special importance if in vitro 
assays are used in the presence of bovine serum. 
4. Conclusions 
In the seven years since this subject waslast reviewed 
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here, relatively little has been added to our knowledge 
about the elusive cell-specific and endogenous inhib- 
itors called ‘chalones’. The epidermal, lymphocytic 
and granulocytic chalones have all been further puri- 
fied, but until very recently (and only in the case of 
the granulocytic chalone) not to anything near 
homogeneity. The major increase in knowledge about 
these chalones is: 
(1) That they are of much smaller size for the most 
part than we had previously perceived and believed; 
i.e ., lymphocyte, granulocyte, and the JB-1 ascites 
chalone are now down to an M, of 600-700, 
while iibroblast chalone is clearly <M, 10 000 
and both the G-2 and G-l epidermal inhibitors 
have been reduced in size (see table 1). This 
reduction in molecular size proceeds from the 
aggregative avidity of many of these chalones for 
various macromolecules. 
(2) One of the major problems in the identification 
of endogenous inhibitors is that most tissues con- 
tain polyamines and that polyamines will inhibit 
the proliferation in vitro of most cell types to 
varying degrees, especially when cultured in fetal 
calf serum. 
Thus, as the chalones themselves ‘shrink’ to smaller 
sizes, small cationic molecules (like spermine and sperm- 
idine) loom larger as major artifacts in the determina- 
tion of specific endogenous mitotic inhibitor capacity 
of various fractions during purification attempts. 
Table 1 
Relative molecular mass estimates for representative chalones 
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38 000 
10 000-30 000 
2000- 3000 
















MI values for selected chalones can be found in references and 
reviews cited in the text 
Volume 120. number 2 FEBS LETTERS November 1980 
References 
[l] Weiss,P.(1952) Science 115,487-488. 
[2] Weiss,P. and Kavanau, J. L. (1957) J. Gen. Physiol. 41, 
l-47. 
[3] Bullough, W. S. and Laurence, E. B. (1960) Proc. Roy. 
Sot. B 151,517~536. 
[4] Bullough, W. S. (1962) Biol. Rev. 37,307-342. 
[S] Iverson, 0. H. (1976) in: Chalones (Houck, J. C. ed) 
pp. 37-70, Elsevier/North-Holland, Amsterdam, 
New York. 
[6] Houck, J. C., ed (1976) Chalones, Elsevier/North- 
Holland, Amsterdam, New York. 
[7] Moorhead, J. F., Paraskova-Tchernozenski, E. Pirrie, 
A. J. and Hayes, C. (1969) Nature 224,1207-1208. 
[8] Jones, J., Paraskova-Tchernozenski, E. and Moorhead, 
J. F. (1970) Lancet i, 654. 
[9] GarciaGiralt, E., Lasalvia, E., Florentin, I. and Mathe, 
G. (1970) Eur. J. Clin. Biol. Res. 15,1012-1015. 
[lo] GarciaGiralt,E., Morales,H., Lasalvia,E. and Mathe, G. 
(1972) J. Immunol. 109,878-880. 
[ll] Kiger, N. (1971) Rev. Eur. Etudes Clin. Biol. 16, 
566-572. 
[12] Houck, J.C., Irausquin,H. and Leikin,S. (1971) Science 
173,1139-1141. 
[13] Attallah, A., Sunshine, G., Hunt, C. and Houck, J. C. 
(1975) Exp. Cell Res. 93,283-292. 
[ 141 Heideman, E., Jung, A. and Wilms, K. (1976) Klin. 
Wochenschr. 54,221-226. 
[ 151 Heideman, E., Jung, A., Masurczak, J., Podgornik, N., 
Schmidt, N. and Wilms, K. (1979) Blut 39,99-106. 
[ 161 Ranney, D. F. (1975) in: Advances in Pharmacy and 
Chemotherapy, (Garattini et al. eds) pp. 359-408, Aca- 
demic Press, New York. 
[ 171 Attallah, A. M. and Houck, J. C. (1976) in: Chalones 
(Houck, J. C. ed) pp. 355-384, Elsevier/North-Holland, 
Amsterdam, New York. 
[18] Houck, J.C. (1978) J. Reticula. Sot. 24,571-581. 
[19] Kiger, N., Florentin, I. and Mathe, G. (1973) Natl. Can- 
cer Inst. Monogr. 38,135-142. 
[20] GarciaGiralt, E., Rella, W., Morales, V. H., Diaz-Rubio, 
E. and Richard, F. (1973) Natl. Cancer Inst. Monogr. 
38,125-130. 
[21] Houck, J. C., Attallah,A. M.and Lilly, J. R. (1973) 
Nature 245,148-149. 
[ 221 Houck, J. C., Kanagalingham, K., Hunt, C., Attallah, 
A. M. and Chung, A. (1977) Science 196,896-897.. 
[23] Lenfant, M., Privat De Garilhe, M., GarciaGiralt, E. and 
Tempie,C. (1976) Biochim. Biophys. Acta 451, 
106-117. 
[24] Grundboeck-Jusko, J. (1976) Acta Biochim. Polon. 23, 
165-170. 
[ 251 Lenfant, M., GarciaCiralt,E., Thomas,M. and Di Giusto, 
L. (1978) Cell Tissue Kinet. 11,455-463. 
[26] Lenfant,M.,Garcia-Giralt,E.,Di Giusto,L.and Thomas, 
M. (1980) Mol. Immunol. 17,119-126. 
(271 Maschler, R. and Maurer, H. R. (1979) HoppeSeyler’s 
Z. Physiol. Chem. 360,735-745. 
[ 281 Patt, L.M., Gleisner, G. M., Barrantes, D. M. and Houck, 
J.C. (1980) submitted. 
[29] Waksmann, B. H. and Namba, Y. (1976) Cell Immunol. 
21,161-176. 
[ 301 Hooper, J. A., McDaniel, M. C., Thurman, G. B., Cohen, 
G. H., Schulof, R. S. and Goldstein, A. L. (1975) Ann 
NY Acad. Sci. 249,125-144. 
[31] Kaufman, D. B. (1980) Clin. Exp. Immunol. 39, 
722-727. 
[32] Low,T.L.K.,Thurman,G.B.,Chincarini,C,McClure, 
J. E., Marshall, G. D., Hu, S.-K. and Goldstein, A. L. 
(1979) Ann. NY Acad. Sci. 332,33-48. 
[33] Bach, J.-F., Dardenne, M., Pleau, J.-M. and Rosa, J. 
(1977) Nature 266,55-57. 
[34] Rytomaa, T. (1976) in: Chalones (Houck, J. C. ed) 
PP. 289-310, Elsevier/North-Holland, Amsterdam, 
New York. 
[35] Paukovits, W. R. (1976) in: Chalones (Houck, J. C. ed) 
pp. 3 1 l-330, Elsevier/North-Holland, Amsterdam, 
New York. 
[36] Maurer, H. R. and Laerum, 0. D. (1976) in: Chalones 
(Houck, J. C. ed) pp. 331-354, Elsevier/North-Holland, 
Amsterdam, New York. 
[37] Paukovits, W. R. (1973) Natl. Cancer Inst. Monogr. 38, 
147-156. 
[ 381 Laerum,O. D. and Maurer, H. R. (1973) Virchows 
Archiv. B. Cell Pathol. 14,293-305. 
[39] Rytomaa, T.and Kiviniemi, (1968) Cell Tiss. Kinet. 1, 
329-339. 
[40] Paukovits, W. R. and Hinterberger, W. (1978) Blut 37, 
7-18. 
[41] Paukovits, W. R., Hinterberger, W. and Paukovits, J. B. 
(1977) Oncology 34,187-189. 
[42] Maschler, R. and Maurer, H. R. (1978) HoppeSeyler’s 
Z. Physiol. Chem. 359,825-834. 
[43] Foe, P., Paile, W., Tse Hing Yuen, T. L. S., Jones, W. A., 
Janne, J. and Rytomaa, T. (1979) Biomedicine 31, 
163-167. 
[44] Laerum, 0. D., Paukovits, W. R., Aardal, N. P. and 
Morild, I. (1979) 14th Conf. Int. Sot. Chronobiology, 
Hannover. 
[45] Paukovits, W. R., Paukovits, J. B., Laerum, 0. D. and 
Hinterberger, W. (1980) IRCS Med. Sci. Biochem. 
305-306. 
[46] Tanapat,P., Gaetjens,E. and Broome, J.D. (1978) Proc. 
Natl. Acad. Sci. USA 75,1849-1853. 
1471 Barfod, N. M. and Bichel, D. (1976) Virchows Arch. B. 
CellPathol. 21,249-259. 
[48] Barfod, N. and Marker, K. (1980) Abst. Xth Meeting 
Eur. Study Group Cell Proliferation in: Cell Tiss. Kinet. 
13,184-185. 
[49] Verley, W. G. (1976) in: Chalones (Houck, J. C. ed) 
pp. 401-428, Elsevier/North-Holland, Amsterdam, 
New York. 
[50] Verley,W.G.,Deschamps,Y.,Pushpathadam,J.and 
Desrosiers,M. (1971) Can. J. Biochem. 49,1376-1383. 
[51] McMahon, J. B.and Iype,P. T. (1980) Cancer Res. 40, 
1249-1254. 
[52] Sekas, G., Owen, W. G. and Cook, R. T. (1979) Exp. 
Res. 122,47-54. 
[53] Gonzales, R. and Verley, W. G. (1978) Eur. J. Cancer 
14,689-697. 
169 
Volume 120, number 2 FEBS LETTERS November 1980 
[54] Bullough,W.S.andMitrani,E.(1976)in: Chalones 
(Houck, J. C. ed) pp. 7-36, Elsevier/NorthHolland, 
Amsterdam, New York. 
[55] Elgjo, K. (1976) in: Chalones (Houck, J. C. ed) pp. 
229-246, Elsevier/North-Holland, Amsterdam, 
New York. 
[56] Marks, F. (1976) in: Chalones (Houck, J. C. ed) pp. 
173-228, Elsevier/NorthHoBand, Amsterdam, 
New York. 
[57] Iverson, 0. H. (1969) in: Homeostatic Regulators 
(Wolstenholme, G.E.W. et al.eds) pp.25-56,Churchill, 
London. 
[58] Laurence, E. B. (1973) Natl. Cancer Inst. Monogr. 38, 
37-46. 
[59] Marks, F. (1975) Hoppe-Seyler’s Z. Physiol. Chem. 356, 
1989-1992. 
[60] Dent,P.B.,Liao,S.K.,Ettin,G.andCleland,G.B. 
(1978) Oncology 35,235-241. 
[61] Mohr, V., Althoff, J., Kinzel, J., Suss, R. and Volm, M. 
(1968) Nature 220,138-139. 
[62] Mohr, V., Hondius-Boldingh, W., Emminger, A. and 
Behagel,H.S.(1972) Cancer Res. 32,1122-1128. 
[63] Mohr, V., Hondius-Boldingh, W. and Althoff, J. (1972) 
Cancer Res. 32,1117-1121. 
[64] Houck, J. C. and Hunt, C. V. (1976) in: Chalones 
(Houck, J. C. ed) pp. 483-491, Elsevier/North-Holland, 
Amsterdam, New York. 
[65] Kasahara, T. and Shioiri-Nakano, K. (1976) J. Immunol. 
116,1251-1156. 
1661 Opitz, H. G., Niethammer, D., Lemke, H., Flad, H. D. 
and Huget, R. (1975) Cell Immunol. 16,379-388. 
[ 671 Opitz, H. G., Niethammer, D., Jackson, R. C., Lemke, 
H., Huget, R. and Flad, H. D. (1975) Cell Immunol. 18, 
70-75. 
[68] Evans, R. and Booth, C. G. (1976) Cell Immunol. 26, 
120-126. 
[69] Allen, J. C., Smith,C. J., Curry, M. C. and Gaugas, J. M. 
(1976) Nature 267,623-625. 
[ 701 Byrd, W. J., Jacobs, D. M. and Amoss, M. S. (1976) 
Nature 267,261-623. 
[71] Gaugas, J. M. and Curzen, P. (1978) Lancet i, 18-20. 
[72] Maurer, H. R. and Maschler, (1979) Z. Naturforsch. 34, 
452-459. 
[73] Allen,J.C.,Smith,C.J.,Hussain,J.I.,Thomas,J.M. 
and Gaugas, J. M. (1979) Eur. J. Biochem. 102, 
153-158. 
[74] Byrd, W. J., Jacobs, D. M. and Amoss, M. S. (1978) in: 
Adv.Polyamine Res. 2,71-83. 
[75] Tabor,K.W.,Tabor,H.andBachrach,V.(1964)J.Biol. 
Chem. 239,2194-2203. 
[76] Alarcon, R. A., Foley, G. E. and Modest, E. J. (1961) 
Arch. Biochem. Biophys. 94,540-541. 
[77] Alarcon, R. A. (1970) Arch. Biochem. Biophys. 137, 
365-372. 
1781 Webber, M. N. and Chaproniere-Rickenberg, D. (1980) 
CelI Biol. Int. Rep. 4,185-193. 
[79] Kimes, B. W. and Morris, D. R. (1971) Biochim. Bio- 
phys. Acta 228,223-234. 
[80] Dearborn, D. G. (1978) Adv. Polyamine Res. 2, 
273-279. 
[81] Blaschko, H. and Bonney, R. (1962) Proc. Roy. Sot. B. 
156,26fl--279. 
[82] Campbell, R. A. (1978) Adv. Polyamine Res. 2. 
[83] Lenfant, M., Di Giusto, L., Oleson, D. L., GarciaGiralt, 
E., Mayadoux, E., Villanueva, V. and Adlakha, R. C. 
(1979) Biomedicine 31,110-113. 
[84] Lenfant,M.,DiGiusto,L.andGarciaGiralt,E.(1979) 
Nature 277,154. 
[85] Rijke,E. 0. and Ballieux, R. E. (1978) Nature 274, 
804-805. 
170 
